|Home||» Products||» Anti Cancer Medicines||» Jakavi Ruxolitinib|
- Brand name: Jakavi
- Active Ingeridents(Generic Name) : Ruxolitinib
- Company Name: Novartis
- Package:14 tabs in strip
- Strength: 5mg
It is used in the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.
Mechanism of action:
Jakavi (Ruxolitinib ) is a Janus kinase inhibitor with selectivity for subtypes JAK1 and JAK2 of this enzyme. Jakavi (Ruxolitinib ) inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.
Dosage and Administration:
Jakavi (Ruxolitinib ) is a pill, taken by mouth, with or without food. Take Jakavi (Ruxolitinib ) exactly as prescribed, even if you are feeling better. Swallow Jakavi (Ruxolitinib ) tablets whole. Do not chew, crush or break.
Side effects include thrombocytopenia (low blood platelet count), anemia (low red blood cell count) and neutropenia; risk of infection; symptom exacerbation if the medication is interrupted or discontinued; and non-melanoma skin cancer.
Immunologic side effects have included herpes zoster (shingles) and case reports of opportunistic infections. Metabolic side effects have included weight gain. Laboratory abnormalities have included alanine transaminase (ALT) abnormalities, aspartate transaminase (AST) abnormalities, and mildly elevated cholesterol levels.
Jakavi (Ruxolitinib ) may interact with many types of medications . Before starting Jakavi (Ruxolitinib ) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
Do not receive any kind of immunization or vaccination without your doctor's approval while taking Jakavi (Ruxolitinib ).
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category C (use in pregnancy only when benefit to the mother outweighs risk to the fetus).
Store: Store Jakavi (Ruxolitinib ) at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light.